Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.

BACKGROUND: Noneosinophilic asthma is common across asthma severities. However, in patients with moderate-to-severe disease, the absence of sputum eosinophilia cannot distinguish between asthmatic subjects with eosinophilic inflammation controlled by corticosteroids versus those in whom eosinophilic...

Full description

Bibliographic Details
Main Authors:	Kulkarni, N, Hollins, F, Sutcliffe, A, Saunders, R, Shah, S, Siddiqui, S, Gupta, S, Haldar, P, Green, R, Pavord, I, Wardlaw, A, Brightling, C
Format:	Journal article
Language:	English
Published:	2010

Similar Items

The significance of eosinophilic airway inflammation in asthma
by: Pavord, I, et al.
Published: (2002)

Eosinophils in asthma and airway hyperresponsiveness.
by: Brightling, C, et al.
Published: (2004)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
by: Brightling, C, et al.
Published: (2003)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
by: Berry, M, et al.
Published: (2005)

Eosinophils in asthma and other allergic diseases.
by: Wardlaw, A, et al.
Published: (2000)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
by: Haldar, P, et al.
Published: (2009)

Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.
by: Brightling, C, et al.
Published: (2000)

Mepolizumab in refractory eosinophilic asthma.
by: Pavord, I, et al.
Published: (2010)

Non-eosinophilic corticosteroid unresponsive asthma.
by: Pavord, I, et al.
Published: (1999)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
by: Berry, M, et al.
Published: (2007)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
by: Shrimanker, R, et al.
Published: (2017)

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
by: Siva, R, et al.
Published: (2007)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2017)

Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.
by: Siddiqui, S, et al.
Published: (2007)

Eosinophils in Asthma and Airway Hyperresponsiveness [3] (multiple letters)
by: Brightling, C, et al.
Published: (2004)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
by: Shrimanker, R, et al.
Published: (2017)

Role of eosinophilic airway inflammation in models of asthma
by: José R Lapa e Silva, et al.
Published: (1997-12-01)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)

Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma.
by: Brightling, C, et al.
Published: (1999)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.
by: Bilocca, D, et al.
Published: (2017)

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
by: Green, R, et al.
Published: (2002)

Biomarkers for severe eosinophilic asthma.
by: Yancey, S, et al.
Published: (2017)

IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis
by: Mistry Vijay, et al.
Published: (2009-07-01)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
by: Haldar, P, et al.
Published: (2014)

New insights into the relationship between airway inflammation and asthma.
by: Wardlaw, A, et al.
Published: (2002)

COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils
by: Eltboli, O, et al.
Published: (2014)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
by: Yancey, S, et al.
Published: (2016)

Eosinophilic bronchitis is an important cause of chronic cough.
by: Brightling, C, et al.
Published: (1999)

Eosinophilic phenotypes of airway disease.
by: Pavord, I
Published: (2013)

CCL4 Regulates Eosinophil Activation in Eosinophilic Airway Inflammation
by: Hanh Hong Chu, et al.
Published: (2022-12-01)

Observational study of the natural history of eosinophilic bronchitis.
by: Berry, M, et al.
Published: (2005)

Eosinophilic inflammation in allergic asthma
by: Samantha Souza Possa, et al.
Published: (2013-04-01)

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.
by: Berry, M, et al.
Published: (2004)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma.
by: Brightling, C, et al.
Published: (2000)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
by: Brightling, C, et al.
Published: (2000)

Glucocorticoids and mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2018)

Galectin-10, a potential biomarker of eosinophilic airway inflammation.
by: Justin C Chua, et al.
Published: (2012-01-01)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
by: Hirofumi Watanabe, et al.
Published: (2020-10-01)